Thu, Mar 5, 2015, 9:39 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Trius Therapeutics, Inc. (TSRX) Message Board

  • chimakot chimakot May 4, 2013 3:24 PM Flag

    ....has a solid chance of approval in the back half of the year,"......

    I thought approval would not happen until 2014, am I wrong or is Cramer wrong? TIA

    "I think their drug Tedizolid, for MRSA skin infections, has a solid chance for approval in the back half of the year," Cramer said. "The company has $100 million in cash to fund commercial operations, and Tedizolid could garner peak sales of $800 million. So I favor the risk reward here, but please use price limits. Biotech investing is tricky, especially within these tiny micro caps."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
13.630.0000(0.00%)Sep 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Geron Corporation
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orexigen Therapeutics, Inc.
NASDAQThu, Mar 5, 2015 4:00 PM EST
Orbital ATK, Inc.
NYSEThu, Mar 5, 2015 4:02 PM EST